Welcome to our dedicated page for Revolution Medicines SEC filings (Ticker: RVMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Revolution Medicines, Inc. filings document a late-stage clinical oncology company focused on RAS-addicted cancers and RAS(ON) inhibitors. Its Form 8-K reports include financial results, clinical-program updates for daraxonrasib and other pipeline candidates, regulatory-related disclosures and material events tied to corporate progress.
The company’s SEC record also covers proxy governance, annual meeting matters, executive compensation, registered securities and capital-structure changes. Disclosures identify Nasdaq-listed common stock and warrants, and material-agreement filings describe convertible senior notes due 2033, related indenture terms and other financing arrangements used to support research and development, administrative expenses and potential commercialization activities.
Revolution Medicines reported the sale of 2,753 shares of Common Stock by a selling party on 03/17/2026, with proceeds shown as $273,869.54.
The filing also lists prior restricted stock unit grants of 318, 846, 840, and 649 shares dated 09/01/2022, 03/01/2023, 03/01/2024, and 03/01/2025, respectively.
Revolution Medicines (RVMD) Rule 144 sale notice reporting insider dispositions. The filing lists recent open‑market sales of Common Stock by Anthony Mancini: 37,450 shares on 03/25/2026, 3,120 shares on 04/27/2026, and 3,121 shares on 05/26/2026, each with an associated dollar amount. The filing also shows a restricted stock unit grant dated 04/01/2025 for 4,211 shares tied to services rendered. Shares outstanding are listed as 212,596,462 as of 06/15/2026 in the provided excerpt.
Stephen Michael Kelsey filed a Form 144 notice to sell 4,071 shares of Common Stock of Revolution Medicines. The filing lists restricted stock unit grants dated 03/01/2023, 03/01/2024, and 03/01/2025 totaling 4,071 units. It also reports that 4,302 shares were sold on 03/17/2026 for $427,964.68.
Revolution Medicines (RVMD) submitted a Form 144 notice reporting proposed sales of Common Stock by an insider. The filing lists two dispositions by Margaret A. Horn: 4,583 shares on 03/17/2026 (proceeds $455,918.67) and 10,000 shares on 06/11/2026 (proceeds $1,480,140.00). The filing also lists restricted stock unit grants of 1,272, 1,304, and 910 shares dated 03/01/2023, 03/01/2024, and 03/01/2025 respectively. Shares outstanding are shown as 212,596,462 as of 06/15/2026.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice relating to the proposed sale of 90,000 shares of Common Stock on 06/15/2026, tied to the exercise of stock options for cash. The filing also lists prior 10b5-1 sales by Margaret A. Horn of 10,000 shares on 06/11/2026 and 4,583 shares on 03/17/2026.
Revolution Medicines, Inc. reported insider activity by Chief Operating Officer Margaret A. Horn. On June 11, 2026, she exercised stock options to acquire a total of 10,000 shares of common stock at exercise prices of $40.74 and $42.45 per share. The same day, she sold 10,000 shares of common stock in open-market transactions at prices ranging from $143.78 to $150.15 per share. The filing notes these trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on March 12, 2026, indicating a planned exercise-and-sell pattern rather than ad hoc trading.
RVMD insider filed a Form 144 to sell 10,000 shares arising from the exercise of stock options on 06/11/2026 for cash. The filing also shows a prior sale of 4,583 shares on 03/17/2026 for $455,918.67.
The notice names an issuer-directed exercise and lists Morgan Stanley Smith Barney LLC as the broker. The filing supplies transaction dates, quantities, and the cash nature of the 06/11/2026 disposition.
Revolution Medicines, Inc. officer Anthony Mancini reported mixed equity transactions in company common stock. He sold a total of 3,121 shares in open-market transactions at weighted average prices in the low $150s per share and exercised stock options for 3,121 shares at an exercise price of $33.62 per share.
The filing shows this activity was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 24, 2025. Following the transactions, Mancini directly holds 54,400 shares of common stock, which a footnote states includes 54,400 Restricted Stock Units, indicating these trades represent a small portion of his overall reported equity position.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice for the proposed sale of 3,121 shares of Common Stock of RVMD on 05/26/2026 arising from an exercise of stock options and to be effected in cash. The filing lists prior 10b5-1 sales by Anthony Mancini: 3,120 shares on 04/27/2026 for $413,128.87 and 37,450 shares on 03/25/2026 for $3,578,821.24.
Janus Henderson Group plc filed Amendment No. 4 to a Schedule 13G/A reporting beneficial ownership of 9,766,496 shares of Revolution Medicines, Inc. common stock, representing 4.9% of the class as of 03/31/2026. The filing states the Asset Managers exercise shared voting and shared dispositive power over the reported shares and disclaims rights to dividends or sale proceeds. The filing notes that none of the Managed Portfolios individually owns more than 5% of the class. The amendment is signed on 5/15/2026.